China Oncology ›› 2023, Vol. 33 ›› Issue (4): 342-353.doi: 10.19401/j.cnki.1007-3639.2023.04.004
• Article • Previous Articles Next Articles
Received:
2022-12-08
Revised:
2023-03-02
Online:
2023-04-30
Published:
2023-05-15
Contact:
CHEN Junxia
CLC Number:
CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism[J]. China Oncology, 2023, 33(4): 342-353.
Tab. 1
Correlation between the relative expression of hsa_circ_0001573 and clinicopathological features in 40 breast cancer patients"
Clinicopathological features | All cases | Relative expression of hsa_circ_0001573 | Chi-square | P value | |
---|---|---|---|---|---|
Low (n=15) | High (n=25) | ||||
Age/year | 2.373 | 0.123 | |||
<55 | 26 | 12 | 14 | ||
≥55 | 14 | 3 | 11 | ||
Grade | 3.175 | 0.075 | |||
Ⅱ | 12 | 7 | 5 | ||
Ⅲ | 28 | 8 | 20 | ||
T stage | 5.184 | 0.023 | |||
T1 | 15 | 9 | 6 | ||
T2-3 | 25 | 6 | 19 | ||
N stage | 7.111 | 0.008 | |||
N0 | 24 | 13 | 11 | ||
N1-3 | 16 | 2 | 14 | ||
TNM stage | 6.222 | 0.013 | |||
Ⅰ | 12 | 8 | 4 | ||
Ⅱ/Ⅲ | 28 | 7 | 21 |
Fig. 2
Expression and localization of hsa_circ_0001573 A: Relative expression of hsa_circ_0001573 in cell lines; ***: P<0.001, compared with MCF-10A; B: Relative expression of hsa_circ_0001573 in 40 cases of breast cancer tissues; *: P<0.05, compared with paracancerous tissues; C: FISH detection (×400)."
Fig. 9
Expression of c-myc was enhanced by the interaction of hsa_circ_0001573 with GNB4 A: RNA pull down; B: FISH-IF (×400); C: The efficiency after transfection with overexpressed GNB4 plasmid or sh-GNB4; D: Relative expression of c-myc after transfection with overexpressed GNB4 plasmid or sh-GNB4; E, F: Western blot; ***: P<0.001, compared with mock or sh-NC; **: P<0.01, compared with mock or sh-NC."
[1] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
doi: 10.3322/caac.v72.1 |
[2] |
BUTTI R, DAS S, GUNASEKARAN V P, et al. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges[J]. Mol Cancer, 2018, 17(1): 34.
doi: 10.1186/s12943-018-0797-x pmid: 29455658 |
[3] |
RAGAN C, GOODALL G J, SHIROKIKH N E, et al. Insights into the biogenesis and potential functions of exonic circular RNA[J]. Sci Rep, 2019, 9(1): 2048.
doi: 10.1038/s41598-018-37037-0 pmid: 30765711 |
[4] |
MO D D, LI X P, RAABE C A, et al. A universal approach to investigate circRNA protein coding function[J]. Sci Rep, 2019, 9(1): 11684.
doi: 10.1038/s41598-019-48224-y pmid: 31406268 |
[5] |
GUO X Q, JIN W, CHANG C F, et al. Large-scale quantitative genomics analyzes the circRNA expression profile and identifies the key circRNA in regulating cell proliferation during the proliferation phase of rat LR[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 2957-2966.
doi: 10.1080/21691401.2019.1640710 pmid: 31315467 |
[6] |
WANG H L, XIAO Y, WU L, et al. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis[J]. Int J Oncol, 2018, 52(3): 743-754.
doi: 10.3892/ijo.2018.4265 pmid: 29431182 |
[7] |
WANG X H, CHEN M H, FANG L. Hsa_circ_0068631 promotes breast cancer progression through c-Myc by binding to EIF4A3[J]. Mol Ther Nucleic Acids, 2021, 26: 122-134.
doi: 10.1016/j.omtn.2021.07.003 |
[8] |
WANG X S, XING L, YANG R, et al. The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC[J]. Mol Cancer, 2021, 20(1): 91.
doi: 10.1186/s12943-021-01383-x pmid: 34116677 |
[9] |
WANG B, LI D P, RODRIGUEZ-JUAREZ R, et al. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells[J]. BMC Cancer, 2018, 18(1): 817.
doi: 10.1186/s12885-018-4711-0 pmid: 30103729 |
[10] |
JI W F, ZHANG W W, WANG X, et al. C-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis[J]. Cell Death Dis, 2020, 11(9): 760.
doi: 10.1038/s41419-020-02980-2 pmid: 32934206 |
[11] | POWER E J, CHIN M L, HAQ M M. Breast cancer incidence and risk reduction in the hispanic population[J]. Cureus, 2018, 10(2): e2235. |
[12] |
WEI C R, WANG Y, LI X Q. The role of Hippo signal pathway in breast cancer metastasis[J]. Onco Targets Ther, 2018, 11: 2185-2193.
doi: 10.2147/OTT |
[13] |
LI X, YANG L, CHEN L L. The biogenesis, functions, and challenges of circular RNAs[J]. Mol Cell, 2018, 71(3): 428-442.
doi: S1097-2765(18)30509-4 pmid: 30057200 |
[14] |
CHENG D, WANG J, DONG Z G, et al. Cancer-related circular RNA: diverse biological functions[J]. Cancer Cell Int, 2021, 21(1): 11.
doi: 10.1186/s12935-020-01703-z pmid: 33407501 |
[15] |
LI J, GAO X Y, ZHANG Z Q, et al. CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502-5p/KRAS and IGF2BP2/Myc axes[J]. Mol Cancer, 2021, 20(1): 138.
doi: 10.1186/s12943-021-01444-1 pmid: 34696797 |
[16] |
MONTALTO F I, DE AMICIS F. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma[J]. Cells, 2020, 9(12): 2648.
doi: 10.3390/cells9122648 |
[1] | BI Zhao, CHEN Peng, QIU Pengfei, CHEN Yuguang, WANG Yongsheng. The analysis of axillary lymph nodes metastasis after neoadjuvant therapy in breast cancer [J]. China Oncology, 2023, 33(4): 361-367. |
[2] | CAO Xiaoshan, CONG Binbin. The research progress of endocrine therapy combined with targeted therapy for triple-positive breast cancer [J]. China Oncology, 2023, 33(3): 288-292. |
[3] | SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109. |
[4] | ZHANG Huiqiang, JIANG Zefei. Key clinical studies on changing clinical practice of advanced breast cancer in 2022 [J]. China Oncology, 2023, 33(2): 110-116. |
[5] | YANG Benlong, JIAO Dechuang, CHEN Jiajian, WANG Chunjian, JIN Lidan, ZHAO Wenhe, GAO Xueqiang, WANG Haibo, LI Jun, ZHAO Haidong, WU Di, FAN Zhimin, WANG Shujun, LIU Zhenzhen, WANG Yongsheng, WU Jiong. Compared the efficacy of mitoxantrone hydrochloride injection for tracing with radionuclide in sentinel lymph node biopsy of breast cancer [J]. China Oncology, 2023, 33(2): 126-133. |
[6] | DUAN Baowei, ZHAO Na, BI Zhao, QIU Pengfei, XU Xinghe, CHEN Yuguang, FAN Qingda, WANG Yongsheng. Radiotracer technique optimization for breast cancer internal mammary sentinel lymph node biopsy [J]. China Oncology, 2023, 33(2): 134-141. |
[7] | CHEN Yuguang, SUN Xiao, BI Zhao, QIU Pengfei, DUAN Baowei, FAN Qingda, WANG Yongsheng. Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation [J]. China Oncology, 2023, 33(2): 142-151. |
[8] | LENG Jie, QIU Guochun, ZHANG Bo, PU Yan. Mechanism of breast cancer centrosome regulatory protein SEC23B on tumor invasion and metastasis [J]. China Oncology, 2023, 33(2): 152-161. |
[9] | FAN Qingda, CONG Binbin, CHEN Yuguang, DUAN Baowei, WANG Yongsheng. Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients [J]. China Oncology, 2023, 33(2): 174-180. |
[10] | GUO Qing, ZHANG Jian. Advances in targeted therapy for HER2-low breast cancer [J]. China Oncology, 2023, 33(2): 181-190. |
[11] | WANG Ziyu, XIAO Yi, JIANG Yizhou, SHAO Zhimin. Advances in fundamental and translational breast cancer research in 2022 [J]. China Oncology, 2023, 33(2): 95-102. |
[12] | ZHANG Jingchen, LI Xin, LI Jiangtao, LI Haiping, CHEN Yanli, NIU Bing, QI Chuanchuan, YE Beibei. LINC02163 targeting miR-338-3p affects proliferation, invasion and migration of breast cancer cells [J]. China Oncology, 2022, 32(9): 818-826. |
[13] | Committee of Breast Cancer Society, Chinese Anti-Cancer Association, Breast Surgeons Committee of Surgeons Branch, Chinese Medical Doctor Association, Committee of Breast Cancer Society, Shanghai Anti-Cancer Association. Expert consensus on oncoplastic surgery of breast tumor and breast reconstruction (2022 edition) [J]. China Oncology, 2022, 32(9): 836-924. |
[14] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[15] | QIU Pengfei, WANG Yongsheng. Precise regional management of breast cancer in the sentinel lymph node era: evolution and prospect [J]. China Oncology, 2022, 32(8): 680-687. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd